CN103635201B - 人gdnf的变体 - Google Patents

人gdnf的变体 Download PDF

Info

Publication number
CN103635201B
CN103635201B CN201280018010.7A CN201280018010A CN103635201B CN 103635201 B CN103635201 B CN 103635201B CN 201280018010 A CN201280018010 A CN 201280018010A CN 103635201 B CN103635201 B CN 103635201B
Authority
CN
China
Prior art keywords
gdnf
seq
variant
cell line
neurotrophic factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280018010.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103635201A (zh
Inventor
梁敦敏
吕继蓉
K.M.默钱特
M.加尼姆
L.M.奥布赖恩
R.C.史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN103635201A publication Critical patent/CN103635201A/zh
Application granted granted Critical
Publication of CN103635201B publication Critical patent/CN103635201B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201280018010.7A 2011-04-11 2012-04-03 人gdnf的变体 Active CN103635201B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474024P 2011-04-11 2011-04-11
US61/474,024 2011-04-11
PCT/US2012/031927 WO2012141936A1 (en) 2011-04-11 2012-04-03 Variants of human gdnf

Publications (2)

Publication Number Publication Date
CN103635201A CN103635201A (zh) 2014-03-12
CN103635201B true CN103635201B (zh) 2016-11-09

Family

ID=45932578

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280018010.7A Active CN103635201B (zh) 2011-04-11 2012-04-03 人gdnf的变体

Country Status (28)

Country Link
US (1) US9243046B2 (cg-RX-API-DMAC7.html)
EP (1) EP2696889B1 (cg-RX-API-DMAC7.html)
JP (1) JP6093345B2 (cg-RX-API-DMAC7.html)
KR (1) KR101554799B1 (cg-RX-API-DMAC7.html)
CN (1) CN103635201B (cg-RX-API-DMAC7.html)
AU (1) AU2012243178B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013026004B1 (cg-RX-API-DMAC7.html)
CA (1) CA2833158C (cg-RX-API-DMAC7.html)
CY (1) CY1119750T1 (cg-RX-API-DMAC7.html)
DK (1) DK2696889T3 (cg-RX-API-DMAC7.html)
EA (1) EA025129B1 (cg-RX-API-DMAC7.html)
ES (1) ES2656020T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171993T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036239T2 (cg-RX-API-DMAC7.html)
IL (1) IL228102A (cg-RX-API-DMAC7.html)
LT (1) LT2696889T (cg-RX-API-DMAC7.html)
ME (1) ME02849B (cg-RX-API-DMAC7.html)
MX (1) MX337206B (cg-RX-API-DMAC7.html)
NO (1) NO2696889T3 (cg-RX-API-DMAC7.html)
PL (1) PL2696889T3 (cg-RX-API-DMAC7.html)
PT (1) PT2696889T (cg-RX-API-DMAC7.html)
RS (1) RS56639B1 (cg-RX-API-DMAC7.html)
SG (1) SG193483A1 (cg-RX-API-DMAC7.html)
SI (1) SI2696889T1 (cg-RX-API-DMAC7.html)
TW (1) TWI583698B (cg-RX-API-DMAC7.html)
UA (1) UA112981C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012141936A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306556B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190142868A1 (en) 2016-05-13 2019-05-16 Instituto de Medicina Moleccular Methods of treating diseases associated with ilc3 cells
US20230022970A1 (en) * 2019-12-19 2023-01-26 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127419A1 (en) * 1995-09-28 2004-07-01 Amgen Methods of using truncated glial cell line-derived neurotrophic factor
CN101775072A (zh) * 2008-05-21 2010-07-14 王尚武 一种融合穿透肽的神经细胞营养因子gdnf

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2119463C (en) 1991-09-20 2003-09-16 Leu-Fen H. Lin Glial cell line-derived neutrophic factor
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
DE19816186A1 (de) 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
ES2545614T3 (es) * 2009-02-06 2015-09-14 Pepscan Systems Bv Proteínas truncadas con nudo de cistina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127419A1 (en) * 1995-09-28 2004-07-01 Amgen Methods of using truncated glial cell line-derived neurotrophic factor
CN101775072A (zh) * 2008-05-21 2010-07-14 王尚武 一种融合穿透肽的神经细胞营养因子gdnf

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
胶质细胞源性神经营养因子与帕金森病;李月娥等;《延安大学学报（医学科学版）》;20090131;10-14 *

Also Published As

Publication number Publication date
IL228102A (en) 2017-04-30
CA2833158A1 (en) 2012-10-18
PL2696889T3 (pl) 2018-04-30
UA112981C2 (uk) 2016-11-25
RS56639B1 (sr) 2018-03-30
NO2696889T3 (cg-RX-API-DMAC7.html) 2018-04-14
IL228102A0 (en) 2013-09-30
TW201245220A (en) 2012-11-16
HUE036239T2 (hu) 2018-06-28
EP2696889A1 (en) 2014-02-19
MX337206B (es) 2016-02-17
ZA201306556B (en) 2015-03-25
US9243046B2 (en) 2016-01-26
CY1119750T1 (el) 2018-06-27
KR101554799B1 (ko) 2015-09-21
JP2014512369A (ja) 2014-05-22
CN103635201A (zh) 2014-03-12
CA2833158C (en) 2018-07-17
AU2012243178A1 (en) 2013-09-05
AU2012243178B2 (en) 2016-09-29
ES2656020T3 (es) 2018-02-22
HRP20171993T1 (hr) 2018-02-09
JP6093345B2 (ja) 2017-03-08
TWI583698B (zh) 2017-05-21
LT2696889T (lt) 2018-02-12
NZ614325A (en) 2015-07-31
BR112013026004A2 (pt) 2016-11-29
SI2696889T1 (en) 2018-01-31
EA201370204A1 (ru) 2014-02-28
PT2696889T (pt) 2018-02-05
ME02849B (me) 2018-01-20
KR20130131470A (ko) 2013-12-03
BR112013026004B1 (pt) 2020-09-29
MX2013011919A (es) 2014-03-27
SG193483A1 (en) 2013-10-30
DK2696889T3 (en) 2018-01-22
EP2696889B1 (en) 2017-11-15
US20130324474A1 (en) 2013-12-05
EA025129B1 (ru) 2016-11-30
WO2012141936A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
CN104394882B (zh) 成纤维细胞生长因子21蛋白
CN102143758B (zh) Fgf21突变体及其用途
CA2693378C (en) Myostatin antagonists
EP3052519B1 (en) Protoxin-ii variants and methods of use
EP3277304B1 (en) Protoxin-ii variants and methods of use
WO2016140859A2 (en) Protoxin-ii variants and methods of use
EP2270141B9 (en) Partial peptide of lacritin
CN103635201B (zh) 人gdnf的变体
HK1190308B (en) Variants of human gdnf
HK1190308A (en) Variants of human gdnf
NZ614325B2 (en) Variants of human gdnf
AU2013231037B2 (en) Myostatin antagonists
HK1250476B (en) Protoxin-ii variants and methods of use
HK1226746A1 (en) Protoxin-ii variants and methods of use
HK1226746B (en) Protoxin-ii variants and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant